<DOC>
	<DOCNO>NCT01901432</DOCNO>
	<brief_summary>This two-part , multicenter , open label , non-randomized , phase Ib/II study ass safety tolerability , Maximum Tolerated Dose preliminary efficacy Givinostat patient JAK2V617F positive Polycythemia Vera . Part A dose find part Part B assess preliminary efficacy . Patients enrol either Part A Part B transition one part allow . Eligible patient study confirm diagnosis Polycythemia Vera accord revise World Health Organization criterion . Only enrolment Part A slow ( i.e . &lt; 5 patient enrol 3 month ) , eligibility part study may expand patient chronic myeloproliferative neoplasm . Study therapy administer 28 day cycle ( 4 week treatment ) . Disease response evaluate accord European LeukemiaNet criterion 3 6 cycle ( i.e . week 12 24 , respectively ) treatment Givinostat part study . All phlebotomy perform first 3 week treatment count assess clinico-haematological response . The study last maximum 24 week treatment . However , completion trial , patient achieve clinical benefit allow continue treatment Givinostat ( dose schedule ) long-term study . Safety monitor visit throughout entire duration study . Treatment administer outpatient basis patient follow regularly physical laboratory test , specify protocol ; case hospitalization , treatment continue interrupted accord Investigators ' decision .</brief_summary>
	<brief_title>A Two-part Study Assess Safety Preliminary Efficacy Givinostat Patients With Polycythemia Vera</brief_title>
	<detailed_description>This two-part , multicenter , open label , non-randomized , phase Ib/II study ass safety tolerability , MTD preliminary efficacy Givinostat patient JAK2V617F positive PV . Part A dose escalation portion study , MTD establish , Part B commence preliminary efficacy Givinostat PV patient establish . Patients enrol either Part A Part B transition one part allow . Only PV patient Part A assigned dose select Part B ( MTD ) may count towards efficacy assessment Part B . Eligible patient study confirm diagnosis PV accord revise WHO criteria JAK2V617F positivity . Only enrolment Part A slow ( i.e . &lt; 5 patient enrol 3 month ) , eligibility part study may expand patient cMPN . After provide informed write consent undertake protocol-related procedure , unique patient identification code ( i.e . patient screen ID combination his/her site ID , study part ID patient screen number , e.g . IT01-A01 ) assign patient identify patient within his/her enrolment confirmation Italfarmaco S.p.A. designee never reuse case screening failure . After enrolment confirmation assignation dose level first drug intake , unique patient identification code ( i.e . patient ID combination patient screen number ID dose level ID , e.g . IT01-A01-DL1 ) assign patient identify patient throughout his/her participation study never reuse case premature drop-out . Study therapy administer 28 day cycle . In fact , `` cycle '' define 4 week treatment . Disease response evaluate accord clinico-haematological ELN criterion 3 6 cycle ( i.e . week 12 24 , respectively ) treatment Givinostat part study . All phlebotomy perform first 3 week treatment count assess clinico-haematological response . The study last maximum 24 week treatment . However , completion trial , patient achieve clinical benefit allow continue treatment Givinostat ( dose schedule ) long-term study ( Study N. : DSC/11/2357/44 ) . Safety monitor visit throughout entire duration study . Treatment administer outpatient basis patient follow regularly physical laboratory test , specify protocol ; case hospitalization , treatment continue interrupted accord Investigators ' decision .</detailed_description>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<criteria>1 . Patients must able provide inform consent willing sign inform consent form ; 2 . Patients must age ≥18 year ; 3 . Patients must confirm diagnosis Polycythemia Vera accord revise World Health Organization criterion ; 4 . Patients must mutate Janus Kinase 2 ( mutation V617F ) positive disease ; 5 . Patients must active/not controlled disease define 1. hematocrit ≥ 45 % hematocrit &lt; 45 % need phlebotomy , 2. platelet count &gt; 400 x109/L , 3. white blood cell count &gt; 10 x109/L ; 6 . Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 Part A , ECOG performance status ≤ 2 Part B within 7 day initiate study drug ; 7 . Female patient childbearing potential negative serum urine pregnancy test within 72 hour first dose study therapy ; 8 . Use effective mean contraception woman childbearing potential men partner childbearing potential ; 9 . Adequate acceptable organ function within 7 day initiate study drug ; 10 . Willingness capability comply requirement study . Note enrolment Part A slow ( i.e . &lt; 5 patient enrol 3 month ) , eligibility part study may expand patient chronic myeloproliferative neoplasm . In case , inclusion criterion 5 modify follow Part A : 5 . Patients must active/not controlled disease define : 1 . Essential Thrombocythemia patient : Platelet count &gt; 600 x109/L ; 2 . Myelofibrosis patient : response accord European Myelofibrosis Network criterion . 1 . Active bacterial mycotic infection require antimicrobial treatment ; 2 . Pregnancy nursing ; 3 . A clinically significant correct QT interval prolongation baseline ; 4 . Use concomitant medication know prolong correct QT interval ; 5 . Clinically significant cardiovascular disease include : 1 . Uncontrolled hypertension despite medical treatment , myocardial infarction , unstable angina within 6 month study start ; 2 . New York Heart Association Grade II great congestive heart failure ; 3 . History cardiac arrhythmia require medication ( irrespective severity ) ; 4 . A history additional risk factor torsade de pointes ; 6 . Known positivity human immunodeficiency ; 7 . Known active hepatitis B virus and/or hepatitis C virus infection ; 8 . Platelet count &lt; 100 x109/L within 14 day enrolment ; 9 . Absolute neutrophil count &lt; 1.2x109/L within 14 day enrolment ; 10 . Serum creatinine &gt; 2 time upper limit normal ; 11 . Total serum bilirubin &gt; 1.5 time upper limit normal except case Gilbert 's disease ; 12 . Serum aspartate aminotransferase/alanine aminotransferase ( AST/ALT ) &gt; 3 time upper limit normal ; 13 . History disease ( include active tumour ) , metabolic dysfunction , physical examination finding , clinical laboratory finding give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication ; 14 . Prior treatment Janus Kinase 2 Histone Deacetylase inhibitor participation interventional clinical trial chronic myeloproliferative neoplasm ; 15 . Systemic treatment chronic myeloproliferative neoplasm aspirin/cardio aspirin ; 16 . Hydroxyurea within 28 day enrolment ; 17 . Interferon alpha within 14 day enrolment ; 18 . Anagrelide within 7 day enrolment ; 19 . Any investigational drug device within 28 day enrolment ; 20 . Patient known hypersensitivity component study therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>chronic myeloproliferative neoplasm</keyword>
	<keyword>Polycythemia Vera</keyword>
	<keyword>Essential Thrombocythemia</keyword>
	<keyword>Primary Myelofibrosis</keyword>
	<keyword>Post-Polycythemia Vera Myelofibrosis</keyword>
	<keyword>Post-Essential Thrombocythemia Myelofibrosis</keyword>
	<keyword>Givinostat</keyword>
</DOC>